Which has preferable valuation & earnings, OKUR or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A

Is OKUR or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media prefer OKUR or TECX?

In the previous week, Tectonic Therapeutic had 5 more articles in the media than OnKure Therapeutics. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 3 mentions for OnKure Therapeutics. Tectonic Therapeutic's average media sentiment score of 1.12 beat OnKure Therapeutics' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OKUR or CAPR more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Capricor Therapeutics N/A -56.60% -43.97%

Does the media favor OKUR or CAPR?

In the previous week, Capricor Therapeutics had 45 more articles in the media than OnKure Therapeutics. MarketBeat recorded 48 mentions for Capricor Therapeutics and 3 mentions for OnKure Therapeutics. Capricor Therapeutics' average media sentiment score of 0.11 beat OnKure Therapeutics' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, EIKN or OKUR?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is EIKN or OKUR more profitable?

Eikon Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A OnKure Therapeutics N/A -49.01% -45.77%

Does the media favor EIKN or OKUR?

In the previous week, Eikon Therapeutics had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 3 mentions for OnKure Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat OnKure Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OnKure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OKUR or ARTV more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media prefer OKUR or ARTV?

In the previous week, Artiva Biotherapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 3 mentions for OnKure Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.70 beat OnKure Therapeutics' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OnKure Therapeutics (OKUR) Competitors

$3.56 +0.02 (+0.56%)

As of 09/3/2026 04:00 PM Eastern

Compare

OKUR vs. TECX, CAPR, PROK, EIKN, and ARTV

Should you buy OnKure Therapeutics stock or one of its competitors? OnKure Therapeutics's main competitors and comparable companies include Tectonic Therapeutic (TECX), Capricor Therapeutics (CAPR), ProKidney (PROK), Eikon Therapeutics (EIKN), and Artiva Biotherapeutics (ARTV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OnKure Therapeutics compare to Tectonic Therapeutic?

OnKure Therapeutics (NASDAQ:OKUR) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Tectonic Therapeutic's return on equity of -35.26% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

In the previous week, Tectonic Therapeutic had 5 more articles in the media than OnKure Therapeutics. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 3 mentions for OnKure Therapeutics. Tectonic Therapeutic's average media sentiment score of 1.12 beat OnKure Therapeutics' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OnKure Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 391.57%. Tectonic Therapeutic has a consensus target price of $77.25, indicating a potential upside of 158.19%. Given OnKure Therapeutics' higher probable upside, equities analysts plainly believe OnKure Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

OnKure Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market.

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Tectonic Therapeutic beats OnKure Therapeutics on 9 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to Capricor Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

OnKure Therapeutics has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Capricor Therapeutics	$22.27M	24.23	-$105.04M	-$2.45	N/A

OnKure Therapeutics' return on equity of -49.01% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Capricor Therapeutics	N/A	-56.60%	-43.97%

OnKure Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 45 more articles in the media than OnKure Therapeutics. MarketBeat recorded 48 mentions for Capricor Therapeutics and 3 mentions for OnKure Therapeutics. Capricor Therapeutics' average media sentiment score of 0.11 beat OnKure Therapeutics' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

OnKure Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 391.57%. Capricor Therapeutics has a consensus price target of $29.15, suggesting a potential upside of 214.12%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe OnKure Therapeutics is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Capricor Therapeutics	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Summary

Capricor Therapeutics beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to ProKidney?

ProKidney (NASDAQ:PROK) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ProKidney currently has a consensus target price of $12.00, suggesting a potential upside of 525.00%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 391.57%. Given ProKidney's stronger consensus rating and higher probable upside, equities analysts clearly believe ProKidney is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

OnKure Therapeutics has lower revenue, but higher earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	652.20	-$68.99M	-$0.55	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

OnKure Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
OnKure Therapeutics	N/A	-49.01%	-45.77%

In the previous week, OnKure Therapeutics had 3 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for OnKure Therapeutics and 0 mentions for ProKidney. ProKidney's average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.

Company	Overall Sentiment
ProKidney	Neutral
OnKure Therapeutics	Neutral

ProKidney has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Summary

ProKidney beats OnKure Therapeutics on 9 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Eikon Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

91.0% of OnKure Therapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eikon Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
OnKure Therapeutics	N/A	-49.01%	-45.77%

In the previous week, Eikon Therapeutics had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 3 mentions for OnKure Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat OnKure Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eikon Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 128.10%. OnKure Therapeutics has a consensus price target of $17.50, indicating a potential upside of 391.57%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Eikon Therapeutics and OnKure Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does OnKure Therapeutics compare to Artiva Biotherapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Artiva Biotherapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 3 mentions for OnKure Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.70 beat OnKure Therapeutics' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OnKure Therapeutics' return on equity of -49.01% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

OnKure Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

91.0% of OnKure Therapeutics shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

OnKure Therapeutics has higher earnings, but lower revenue than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Artiva Biotherapeutics	$250K	2,176.58	-$83.86M	-$3.30	N/A

OnKure Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 391.57%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 250.40%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Artiva Biotherapeutics beats OnKure Therapeutics on 8 of the 15 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$143M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.02	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.84	16.29	12.89	6.14
Net Income	-$59.52M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-6.07%	0.34%	0.60%	-0.27%
1 Month Performance	-13.17%	8.52%	5.73%	0.68%
1 Year Performance	32.34%	52.66%	25.35%	14.84%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	2.8534 of 5 stars	$3.56 +0.6%	$17.50 +391.6%	+25.8%	$143M	N/A	N/A	N/A
TECX Tectonic Therapeutic	3.0931 of 5 stars	$31.22 +4.3%	$77.80 +149.2%	+83.2%	$585.31M	N/A	N/A	120	Positive News Analyst Forecast
CAPR Capricor Therapeutics	3.0801 of 5 stars	$10.01 +1.0%	$29.15 +191.2%	+47.8%	$576.16M	$22.27M	N/A	101	Trending News Analyst Upgrade
PROK ProKidney	1.4016 of 5 stars	$1.85 -2.1%	$12.00 +548.6%	-18.6%	$571.39M	$890K	N/A	3
EIKN Eikon Therapeutics	3.6664 of 5 stars	$10.88 +4.0%	$25.00 +129.8%	N/A	$566.57M	N/A	N/A	384	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. TECX, CAPR, PROK, EIKN, and ARTV

How does OnKure Therapeutics compare to Tectonic Therapeutic?

Summary

How does OnKure Therapeutics compare to Capricor Therapeutics?

Summary

How does OnKure Therapeutics compare to ProKidney?

Summary

How does OnKure Therapeutics compare to Eikon Therapeutics?

Summary

How does OnKure Therapeutics compare to Artiva Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. TECX, CAPR, PROK, EIKN, and ARTV

How does OnKure Therapeutics compare to Tectonic Therapeutic?

Which has preferable valuation & earnings, OKUR or TECX?

Is OKUR or TECX more profitable?

Does the media prefer OKUR or TECX?

Do analysts rate OKUR or TECX?

Which has more risk and volatility, OKUR or TECX?

Do insiders and institutionals have more ownership in OKUR or TECX?

Summary

How does OnKure Therapeutics compare to Capricor Therapeutics?

Which has higher earnings and valuation, OKUR or CAPR?

Is OKUR or CAPR more profitable?

Which has more risk and volatility, OKUR or CAPR?

Does the media favor OKUR or CAPR?

Do institutionals and insiders hold more shares of OKUR or CAPR?

Do analysts rate OKUR or CAPR?

Summary

How does OnKure Therapeutics compare to ProKidney?

Do institutionals and insiders have more ownership in PROK or OKUR?

Do analysts prefer PROK or OKUR?

Which has better earnings and valuation, PROK or OKUR?

Is PROK or OKUR more profitable?

Does the media refer more to PROK or OKUR?

Which has more volatility and risk, PROK or OKUR?

Summary

How does OnKure Therapeutics compare to Eikon Therapeutics?

Which has preferable valuation & earnings, EIKN or OKUR?

Do institutionals & insiders believe in EIKN or OKUR?

Is EIKN or OKUR more profitable?

Does the media favor EIKN or OKUR?

Do analysts prefer EIKN or OKUR?

Summary

How does OnKure Therapeutics compare to Artiva Biotherapeutics?

Does the media prefer OKUR or ARTV?

Is OKUR or ARTV more profitable?

Which has more volatility and risk, OKUR or ARTV?

Do insiders and institutionals have more ownership in OKUR or ARTV?

Which has better valuation & earnings, OKUR or ARTV?

Do analysts prefer OKUR or ARTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools